Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation by Okarmus, J, Bogetofte, H, Schmidt, SI, Ryding, M, García-López, S, Ryan, BJ, Martínez-Serrano, A, Hyttel, P, Meyer, M

Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism by Okarmus, J, Havelund, JF, Ryding, M, Schmidt, SI, Bogetofte, H, Heon-Roberts, R, Wade-Martins, R, Cowley, SA, Ryan, BJ, Færgeman, NJ, Hyttel, P, Meyer, M

Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation by Bogetofte, H, Jensen, P, Okarmus, J, Schmidt, SI, Agger, M, Ryding, M, Nørregaard, P, Fenger, C, Zeng, X, Graakjær, J, Ryan, BJ, Wade-Martins, R, Larsen, MR, Meyer, M

PARK2 mutation causes metabolic disturbances and impaired survival of human iPSC-derived neurons by Bogetofte, H, Jensen, P, Ryding, M, Schmidt, SI, Okarmus, J, Ritter, L, Worm, CS, Hohnholt, MC, Azevedo, C, Roybon, L, Bak, LK, Waagepetersen, H, Ryan, BJ, Wade-Martins, R, Larsen, MR, Meyer, M